{"gene":"ARID3B","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1999,"finding":"ARID3B (Bdp) binds to the COOH-terminal region of hypophosphorylated retinoblastoma protein (pRb) through its conserved region, and also binds to the matrix attachment region (MAR) of the immunoglobulin heavy-chain locus, implicating it in transcriptional regulation of differentiation and tissue-specific genes.","method":"Co-immunoprecipitation, DNA binding assay (MAR binding)","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal binding demonstrated by Co-IP and DNA binding assay in single study","pmids":["10446990"],"is_preprint":false},{"year":2006,"finding":"ARID3B is required for survival of neural crest during embryogenesis, can immortalize mouse embryonic fibroblasts (MEFs) on its own, and confers malignancy to MEFs when co-expressed with MYCN, demonstrating oncogenic activity and a cooperative role with MYCN in malignant transformation.","method":"siRNA knockdown in neuroblastoma cell lines, antisense inhibition, transfection/overexpression, in vivo tumor growth assay in nude mice","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (siRNA, antisense, overexpression, in vivo xenograft) in single rigorous study","pmids":["16951138"],"is_preprint":false},{"year":2011,"finding":"Arid3b is expressed in the apical ectodermal ridge (AER) and regulates cell motility and actin cytoskeleton distribution; interference with Arid3b activity causes aberrant AER development due to defective cell movements without changes in cell number or major signaling pathway gene expression.","method":"Loss-of-function in mouse and chick embryos (interference constructs), in vitro motility assay, actin cytoskeleton staining (phalloidin), DiI labeling of progenitor cells in vivo","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including in vivo lineage tracing, in vitro motility assay, and cytoskeletal analysis","pmids":["21307092"],"is_preprint":false},{"year":2012,"finding":"ARID3B full-length isoform (Fl) is predominantly nuclear but also present at the plasma membrane and cytosol; a novel splice form (Sh) lacking C-terminal exons 5-9 accumulates in cytosol and membrane when overexpressed. ARID3B Fl overexpression induces TNFα-mediated apoptosis by upregulating pro-apoptotic genes (BIM, TNFα, TRAIL, TRADD, TNF-R2, Caspase 10, Caspase 7), while ARID3B Sh does not induce apoptosis.","method":"Subcellular fractionation, overexpression of isoforms, gene expression analysis, cell viability assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 — localization by fractionation tied to distinct functional outcomes, single lab","pmids":["22860069"],"is_preprint":false},{"year":2012,"finding":"ARID3B is a direct target of miR-125b; restoration of miR-125b in MCF7 breast cancer cells decreases ARID3B expression and reduces cell motility and migration. Transient silencing of ARID3B phenocopies miR-125b's effect on cell migration.","method":"miRNA overexpression, siRNA knockdown of ARID3B, wound closure and transwell migration assays, phalloidin staining","journal":"Cell structure and function","confidence":"Medium","confidence_rationale":"Tier 2 — miRNA-target relationship validated by KD phenocopy, single lab","pmids":["22307404"],"is_preprint":false},{"year":2012,"finding":"In mouse ES cells, Arid3b promotes cell survival (avoiding cell death) while MYCN drives cell cycle progression; epigenetic switching from H3K27me3 to H3K4me3 at the Arid3b and Mycn promoters occurs during somatic reprogramming to iPS cells, and the reverse switch occurs during neural crest differentiation.","method":"Gene expression analysis in ES cells, siRNA knockdown, ChIP for histone marks (H3K27me3, H3K4me3), reprogramming assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and functional knockdown, single lab","pmids":["22751132"],"is_preprint":false},{"year":2014,"finding":"ARID3B increases ovarian tumor burden in vivo, promotes expression of cancer stem cell markers (CD44, LGR5, CD133/PROM1, Notch2), expands the CD133+ cell population, and enhances paclitaxel resistance.","method":"Intraperitoneal xenograft in nude mice, flow cytometry for CD133+, gene expression profiling of ascites cells, drug resistance assay","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — in vivo tumor model with multiple cellular phenotype readouts, single rigorous study","pmids":["25327563"],"is_preprint":false},{"year":2014,"finding":"Arid3b is expressed in the myocardium and second heart field progenitors; Arid3b-deficient embryos show cardiac pole shortening, absence of myocardial differentiation, and failed epithelial-to-mesenchymal transition in the atrioventricular canal, with defective second heart field progenitor cell addition to the heart. Downstream targets identified include Bhlhb2 and Lims2.","method":"Conditional knockout mouse model, DiI labeling of second heart field progenitors, RNA microarray, histological and immunofluorescence analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — in vivo lineage tracing, KO phenotype with defined cellular mechanism, transcriptomic target identification","pmids":["25336743"],"is_preprint":false},{"year":2015,"finding":"ARID3B directly binds to a defined AT-rich sequence motif at target gene promoters/enhancers (including EGFR enhancer and WNT5A/FZD5 promoter) and induces their expression. ARID3B-driven FZD5 upregulation increases ovarian cancer cell adhesion to extracellular matrix components (collagen IV, fibronectin, vitronectin), with adhesion to collagens II and IV requiring FZD5.","method":"ChIP followed by microarray (ChIP-chip), quantitative RT-PCR, motif-finding analysis, overexpression and knockdown, adhesion assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide ChIP combined with functional validation by overexpression and KD, multiple orthogonal methods","pmids":["26121572"],"is_preprint":false},{"year":2015,"finding":"ARID3B and ARID3A bind to putative ARID3-binding sites in p53 target genes (PUMA, PIG3, p53) in vitro and in vivo; ARID3B silencing blocks transcriptional activation of pro-apoptotic p53 target genes and blocks apoptosis following DNA damage, while ARID3B (but not ARID3A) overexpression induces apoptosis.","method":"ChIP (in vivo binding), EMSA (in vitro binding), siRNA knockdown, overexpression, apoptosis assays after DNA damage","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo binding combined with loss-of-function phenotype, single lab","pmids":["26519881"],"is_preprint":false},{"year":2016,"finding":"Let-7 miRNA directly represses ARID3B, ARID3A, and importin-9 expression. In the absence of let-7, importin-9 facilitates nuclear import of ARID3A, which forms a complex with ARID3B; the nuclear ARID3B complex recruits histone demethylase KDM4C to reduce H3K9me3 and promotes transcription of stemness factors. ARID3B expression is critical for tumor initiation in let-7-depleted cancer cells.","method":"Luciferase reporter assay for miRNA targeting, Co-immunoprecipitation of ARID3A/ARID3B/KDM4C complex, ChIP for H3K9me3, nuclear import assay, tumor initiation assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — complex identified by Co-IP, chromatin modification by ChIP, functional rescue experiments, multiple orthogonal methods","pmids":["26776511"],"is_preprint":false},{"year":2016,"finding":"Conditional deletion of Arid3b in mouse bone marrow decreases common lymphoid progenitors and downstream B cell populations while leaving T cell and myeloid lineages intact, and HSC populations are unperturbed, establishing a specific, cell-autonomous role for Arid3b in B cell development.","method":"Conditional knockout mouse model, flow cytometry of bone marrow populations","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — clean conditional KO with defined cellular phenotype, single lab","pmids":["27537840"],"is_preprint":false},{"year":2016,"finding":"KSHV lytic switch protein RTA upregulates ARID3B expression; ARID3B relocalizes to viral replication compartments upon lytic reactivation and directly binds A/T-rich elements in the KSHV lytic origin of replication (oriLyt) in a lytic cycle-dependent manner. ARID3B knockdown enhances and overexpression inhibits lytic reactivation.","method":"SILAC-based quantitative proteomics, siRNA knockdown, overexpression, DNA affinity assay, ChIP for oriLyt binding, immunofluorescence for relocalization","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including proteomics discovery, ChIP, DNA affinity assay, and bidirectional functional perturbation","pmids":["27512077"],"is_preprint":false},{"year":2019,"finding":"In human trophoblast cells, ARID3A, ARID3B, and KDM4C form a triprotein complex (ARID3B-complex) that binds to promoter regions of HMGA1, c-MYC, VEGF-A, and WNT1. ARID3B knockout disrupts this complex and decreases expression of these target genes. LIN28/let-7 axis regulates this complex upstream.","method":"Co-immunoprecipitation, ChIP, CRISPR knockout of ARID3B, LIN28 double knockout and double knockin cell lines, qRT-PCR","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1-2 — complex formation validated by Co-IP, promoter binding by ChIP, KO rescue approach with multiple orthogonal methods","pmids":["31415216"],"is_preprint":false},{"year":2020,"finding":"ARID3A and ARID3B regulate nearly identical gene sets in ovarian cancer cells, including stemness/cancer genes (Twist, MYCN, MMP2, GLI2, TIMP3, WNT5B); each induces expression of the other, providing evidence of cooperativity. High-level ARID3B (but not ARID3A) induces cell death.","method":"Lentiviral transduction with ARID3A-GFP and ARID3B-RFP, RNA-sequencing, expression analysis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide RNA-seq with defined overexpression, single lab","pmids":["32061921"],"is_preprint":false},{"year":2021,"finding":"ARID3B directly binds to ARID3-binding sites in the promoters of E2F target genes (Cdc2, cyclin E1, p107) in living cells; ARID3B knockdown blocks transcription of these genes and attenuates cell cycle progression. ARID3B overexpression activates cyclin E1 transcription cooperatively with E2F1 and induces cell death.","method":"ChIP for direct binding, luciferase reporter assays with ARID3-BS mutations, siRNA knockdown, overexpression, cell cycle analysis","journal":"International journal of oncology","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding confirmed by ChIP and mutational reporter assay, KD with defined cell cycle phenotype","pmids":["33649863"],"is_preprint":false},{"year":2023,"finding":"ARID3B overexpression increases the expression of lncRNAs MALAT1 and NORAD in NSCLC cells, placing ARID3B upstream of these lncRNAs in the pRB-E2F and p53 regulatory pathways.","method":"Overexpression of ARID3A and ARID3B, qRT-PCR/expression analysis of lncRNAs","journal":"Pathology, research and practice","confidence":"Low","confidence_rationale":"Tier 3 — overexpression with expression readout only, single method, single lab","pmids":["37977034"],"is_preprint":false},{"year":2025,"finding":"ARID3B undergoes liquid-liquid phase separation (LLPS) to form granules both in vivo and in vitro; this ARID3B-mediated LLPS recruits coactivators SMAD2/3 and establishes enhancer activity necessary for initiating gene expression related to nonsyndromic cleft lip/palate (nsCL/P). Disruption of LLPS rescues migration, apoptosis, and phenotype deficits in zebrafish models.","method":"LLPS assays in vitro and in vivo, Co-IP for SMAD2/3 interaction, ChIP for enhancer activity, zebrafish loss-of-function model","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — LLPS and coactivator recruitment demonstrated with in vivo functional rescue, single study","pmids":["41032419"],"is_preprint":false},{"year":2026,"finding":"Phosphorylation of ARID3B at Serine 89 controls its subcellular localization: phosphorylated ARID3B is confined to the nucleus, while unphosphorylated ARID3B can localize to the nucleus, cytoplasm, and membrane. Phospho-mimetic S89D mirrors wild-type ARID3B in transcriptional regulation and chromatin binding, while phospho-dead S89A shows divergent regulation consistent with altered localization.","method":"Site-directed mutagenesis (S89A, S89D phospho-dead/mimetic constructs), phospho-specific antibody generation, subcellular fractionation, ChIP, functional transcriptional assays in ovarian cancer and glioblastoma cells","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with phospho-specific antibody, fractionation, and ChIP functional validation in multiple cell lines","pmids":["41972703"],"is_preprint":false}],"current_model":"ARID3B is a nuclear DNA-binding transcription factor that binds AT-rich sequence motifs at promoters and enhancers to activate target gene expression (including stemness factors, E2F targets, and pro-apoptotic p53 targets); it forms a triprotein complex with ARID3A and the histone demethylase KDM4C to reduce H3K9me3 and promote chromatin accessibility, is regulated upstream by the LIN28/let-7 miRNA axis and by phosphorylation at Serine 89 (which controls its nuclear confinement), undergoes liquid-liquid phase separation to recruit coactivators such as SMAD2/3, and interacts with hypophosphorylated pRb; loss of ARID3B impairs B cell development, cardiac second heart field deployment, and apical ectodermal ridge maturation, while its overexpression expands cancer stem cell populations and promotes malignant transformation."},"narrative":{"teleology":[{"year":1999,"claim":"Establishing ARID3B as a DNA-binding factor with links to cell differentiation: before this work, ARID3B had no known molecular function; Co-IP and DNA binding assays showed it binds hypophosphorylated pRb and the MAR element of the immunoglobulin heavy-chain locus, placing it at the intersection of chromatin architecture and differentiation gene regulation.","evidence":"Co-immunoprecipitation with pRb and MAR DNA binding assay in vitro","pmids":["10446990"],"confidence":"Medium","gaps":["No reciprocal validation of the pRb interaction by independent groups","Functional consequence of pRb binding on transcription not tested","MAR binding specificity relative to other ARID family members unknown"]},{"year":2006,"claim":"Demonstrating oncogenic potential: it was unknown whether ARID3B had transforming activity; overexpression immortalized MEFs and cooperated with MYCN to induce tumors in vivo, establishing ARID3B as an oncogene with cooperative activity in malignant transformation.","evidence":"siRNA/antisense knockdown in neuroblastoma cells, MEF overexpression, and nude mouse xenograft","pmids":["16951138"],"confidence":"High","gaps":["Mechanism of immortalization (bypass of senescence versus anti-apoptosis) not resolved","Identity of transcriptional targets mediating cooperation with MYCN unknown at this stage"]},{"year":2011,"claim":"Defining a developmental morphogenetic role: ARID3B's function in embryonic limb development was unexplored; loss-of-function in mouse and chick showed ARID3B is required for AER cell motility and actin cytoskeleton organization, without affecting proliferation or major signaling pathways.","evidence":"Loss-of-function constructs in mouse/chick embryos, DiI lineage tracing, phalloidin staining, motility assays","pmids":["21307092"],"confidence":"High","gaps":["Direct transcriptional targets controlling motility in AER not identified","Whether ARID3B acts through the same ARID3A/KDM4C complex in this context unknown"]},{"year":2012,"claim":"Linking isoforms and subcellular localization to distinct functional outputs: the full-length nuclear isoform induces TNFα-mediated apoptosis by upregulating pro-apoptotic genes, whereas a short splice form lacking the C-terminal domain does not, establishing that ARID3B's nuclear transcriptional activity is required for its apoptotic function.","evidence":"Subcellular fractionation, isoform overexpression, gene expression and viability assays","pmids":["22860069"],"confidence":"Medium","gaps":["Only overexpression used; endogenous isoform ratios and regulation not characterized","Direct DNA binding by the short isoform not tested"]},{"year":2012,"claim":"Connecting ARID3B to epigenetic reprogramming and stemness: ChIP demonstrated bivalent histone switching (H3K27me3 ↔ H3K4me3) at the Arid3b promoter during iPS reprogramming and neural crest differentiation, placing ARID3B within the epigenetic circuitry governing pluripotency and lineage commitment.","evidence":"ChIP for H3K27me3/H3K4me3 in mouse ES cells, iPS reprogramming, siRNA knockdown","pmids":["22751132"],"confidence":"Medium","gaps":["Whether ARID3B is a cause or consequence of the histone mark switch unresolved","Downstream survival targets in ES cells not identified"]},{"year":2014,"claim":"Establishing a cardiac developmental requirement: conditional knockout revealed ARID3B is essential for second heart field progenitor addition and epithelial-to-mesenchymal transition in the atrioventricular canal, identifying Bhlhb2 and Lims2 as downstream targets.","evidence":"Conditional knockout mouse, DiI labeling of second heart field progenitors, RNA microarray, histology","pmids":["25336743"],"confidence":"High","gaps":["Direct binding to Bhlhb2/Lims2 promoters not shown","Whether the ARID3A/KDM4C complex is involved in cardiac targets unknown"]},{"year":2014,"claim":"Demonstrating cancer stem cell expansion: ARID3B overexpression expanded CD133+ cells, upregulated stemness markers, and conferred paclitaxel resistance in vivo, linking its transcriptional activity to therapy-resistant cancer stem cell phenotypes.","evidence":"Intraperitoneal xenograft, flow cytometry for CD133+, gene expression profiling, drug resistance assay","pmids":["25327563"],"confidence":"High","gaps":["Direct versus indirect regulation of stemness markers not distinguished","Whether ARID3B acts independently of ARID3A in this context not tested"]},{"year":2015,"claim":"Defining direct genomic targets and a DNA-binding motif: ChIP-chip identified genome-wide ARID3B binding at AT-rich motifs in promoters and enhancers (e.g., EGFR enhancer, WNT5A/FZD5 promoter), and functional assays showed ARID3B-driven FZD5 expression promotes cell–matrix adhesion.","evidence":"ChIP-chip, motif analysis, overexpression/knockdown, adhesion assays in ovarian cancer cells","pmids":["26121572"],"confidence":"High","gaps":["Genome-wide binding map limited to one cell line","Co-factor requirements for binding specificity not addressed"]},{"year":2015,"claim":"Connecting ARID3B to p53-dependent apoptotic transcription: ARID3B directly binds ARID3 sites in p53 target gene promoters (PUMA, PIG3), and its silencing blocks pro-apoptotic transcription after DNA damage, revealing ARID3B as a required co-activator of p53 apoptotic targets.","evidence":"ChIP and EMSA for direct binding, siRNA knockdown, overexpression, apoptosis assays after DNA damage","pmids":["26519881"],"confidence":"Medium","gaps":["Physical interaction with p53 protein not demonstrated","Whether ARID3B is needed at all p53 targets or a specific subset unclear"]},{"year":2016,"claim":"Elucidating the ARID3B–ARID3A–KDM4C complex and its upstream regulation by let-7: Co-IP identified a triprotein complex whose nuclear assembly depends on importin-9 (itself a let-7 target); the complex reduces H3K9me3 and activates stemness genes, and ARID3B is required for tumor initiation in let-7-depleted cells.","evidence":"Co-IP, ChIP for H3K9me3, luciferase miRNA reporter, nuclear import assay, tumor initiation assay","pmids":["26776511"],"confidence":"High","gaps":["Stoichiometry and structure of the triprotein complex not determined","Whether KDM4C recruitment is direct or bridged through ARID3A unknown"]},{"year":2016,"claim":"Establishing a specific B-lineage requirement: conditional deletion in bone marrow depleted common lymphoid progenitors and downstream B cells without affecting T or myeloid lineages, defining a cell-autonomous role for ARID3B in B lymphopoiesis.","evidence":"Conditional knockout mouse, flow cytometry of bone marrow populations","pmids":["27537840"],"confidence":"Medium","gaps":["Target genes mediating B cell specification not identified","Functional redundancy with ARID3A in B lineage not tested"]},{"year":2016,"claim":"Revealing a role in viral DNA replication: ARID3B binds AT-rich elements in the KSHV lytic origin of replication in a lytic cycle-dependent manner and inhibits lytic reactivation, demonstrating that its DNA-binding activity is co-opted during herpesvirus infection.","evidence":"SILAC proteomics, ChIP for oriLyt, DNA affinity assay, bidirectional perturbation (siRNA/overexpression), immunofluorescence","pmids":["27512077"],"confidence":"High","gaps":["Mechanism by which ARID3B inhibits lytic reactivation not resolved","Whether the ARID3A/KDM4C complex participates in viral replication control unknown"]},{"year":2019,"claim":"Validating the triprotein complex in a non-cancer developmental context: in trophoblast cells, ARID3B knockout disrupted the ARID3A/ARID3B/KDM4C complex and decreased expression of HMGA1, c-MYC, VEGF-A, and WNT1, confirming the complex as a broadly utilized transcriptional activation module under LIN28/let-7 control.","evidence":"Co-IP, ChIP, CRISPR knockout, LIN28 double KO/KI lines, qRT-PCR in trophoblast cells","pmids":["31415216"],"confidence":"High","gaps":["Whether ARID3B is limiting for complex assembly or acts catalytically not established","Global chromatin accessibility changes upon ARID3B KO not assessed"]},{"year":2021,"claim":"Establishing ARID3B as a direct co-activator of E2F target genes: ChIP and mutational reporter assays showed ARID3B binds ARID3 sites in E2F target promoters (Cdc2, cyclin E1, p107) and cooperates with E2F1 to activate transcription; its knockdown arrests cell cycle progression.","evidence":"ChIP, luciferase reporter with ARID3-BS mutations, siRNA knockdown, overexpression, cell cycle analysis","pmids":["33649863"],"confidence":"High","gaps":["Physical interaction between ARID3B and E2F1 not shown","Whether the ARID3B–E2F cooperation requires KDM4C unknown"]},{"year":2025,"claim":"Discovering liquid–liquid phase separation as a mechanism for enhancer activation: ARID3B forms LLPS granules that recruit SMAD2/3 coactivators to establish enhancer activity required for craniofacial gene expression; disruption of LLPS rescues developmental defects in zebrafish, linking phase separation to nonsyndromic cleft lip/palate.","evidence":"In vitro and in vivo LLPS assays, Co-IP for SMAD2/3, ChIP for enhancer marks, zebrafish loss-of-function model","pmids":["41032419"],"confidence":"Medium","gaps":["Structural determinants of ARID3B phase separation not mapped","Whether LLPS is required at all ARID3B-bound enhancers or context-specific unknown","Confirmation in mammalian craniofacial models pending"]},{"year":2026,"claim":"Identifying Ser89 phosphorylation as a regulatory switch for nuclear confinement: phospho-Ser89 confines ARID3B to the nucleus, while dephosphorylation permits cytoplasmic and membrane localization; phospho-mimetic S89D recapitulates wild-type transcriptional activity and chromatin binding, establishing post-translational control of ARID3B localization and function.","evidence":"Site-directed mutagenesis (S89A/S89D), phospho-specific antibody, subcellular fractionation, ChIP, transcriptional assays in multiple cell lines","pmids":["41972703"],"confidence":"High","gaps":["Identity of the kinase(s) phosphorylating Ser89 unknown","Whether phosphorylation affects LLPS or complex formation with ARID3A/KDM4C not tested"]},{"year":null,"claim":"Key unresolved questions include the identity of the kinase controlling Ser89 phosphorylation, the structural basis of the ARID3A/ARID3B/KDM4C complex, whether LLPS-mediated enhancer activation is a general or tissue-specific mechanism, and the full extent of functional redundancy versus specialization between ARID3A and ARID3B across developmental and oncogenic contexts.","evidence":"","pmids":[],"confidence":"Low","gaps":["Ser89 kinase identity unknown","No structural model of the triprotein complex","LLPS contribution to non-craniofacial gene programs untested","Systematic comparison of ARID3A vs ARID3B genome-wide binding and function lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,8,9,12,15]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[8,9,10,13,15]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,10,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,18]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,18]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,9,10,13,15]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[5,10,13]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[15]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,7,11]}],"complexes":["ARID3A/ARID3B/KDM4C complex"],"partners":["ARID3A","KDM4C","RB1","SMAD2","SMAD3","E2F1","IPO9"],"other_free_text":[]},"mechanistic_narrative":"ARID3B is a nuclear AT-rich interaction domain (ARID) transcription factor that binds AT-rich sequence motifs at promoters and enhancers to activate diverse gene programs—including E2F cell cycle targets, p53 pro-apoptotic targets, stemness factors, and developmental regulators—thereby controlling cell survival, proliferation, and differentiation [PMID:26121572, PMID:33649863, PMID:26519881]. ARID3B forms a triprotein complex with ARID3A and the histone demethylase KDM4C, reducing H3K9me3 to promote chromatin accessibility at target loci; this complex is regulated upstream by the LIN28/let-7 miRNA axis, and ARID3B nuclear confinement is governed by phosphorylation at Serine 89 [PMID:26776511, PMID:31415216, PMID:41972703]. ARID3B undergoes liquid–liquid phase separation to recruit coactivators such as SMAD2/3 and establish enhancer activity, linking its biophysical properties to transcriptional activation during craniofacial development and nonsyndromic cleft lip/palate [PMID:41032419]. Loss of ARID3B impairs B cell development, cardiac second heart field deployment, and apical ectodermal ridge morphogenesis, while its overexpression expands cancer stem cell populations, cooperates with MYCN in malignant transformation, and promotes chemoresistance [PMID:27537840, PMID:25336743, PMID:21307092, PMID:16951138, PMID:25327563]."},"prefetch_data":{"uniprot":{"accession":"Q8IVW6","full_name":"AT-rich interactive domain-containing protein 3B","aliases":["Bright and dead ringer protein","Bright-like protein"],"length_aa":561,"mass_kda":60.6,"function":"Transcription factor which may be involved in neuroblastoma growth and malignant transformation. Favors nuclear targeting of ARID3A","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8IVW6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARID3B","classification":"Not Classified","n_dependent_lines":50,"n_total_lines":1208,"dependency_fraction":0.041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ARID3B","total_profiled":1310},"omim":[{"mim_id":"620868","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3C; ARID3C","url":"https://www.omim.org/entry/620868"},{"mim_id":"612457","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3B; ARID3B","url":"https://www.omim.org/entry/612457"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":23.2}],"url":"https://www.proteinatlas.org/search/ARID3B"},"hgnc":{"alias_symbol":["BDP","DRIL2"],"prev_symbol":[]},"alphafold":{"accession":"Q8IVW6","domains":[{"cath_id":"1.10.150.60","chopping":"199-324","consensus_level":"high","plddt":93.9391,"start":199,"end":324}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IVW6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IVW6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IVW6-F1-predicted_aligned_error_v6.png","plddt_mean":57.97},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARID3B","jax_strain_url":"https://www.jax.org/strain/search?query=ARID3B"},"sequence":{"accession":"Q8IVW6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8IVW6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8IVW6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IVW6"}},"corpus_meta":[{"pmid":"23489259","id":"PMC_23489259","title":"GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study.","date":"2013","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/23489259","citation_count":166,"is_preprint":false},{"pmid":"25264814","id":"PMC_25264814","title":"Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging.","date":"2015","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/25264814","citation_count":96,"is_preprint":false},{"pmid":"32455665","id":"PMC_32455665","title":"The Role of LIN28-let-7-ARID3B Pathway in Placental Development.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32455665","citation_count":50,"is_preprint":false},{"pmid":"26776511","id":"PMC_26776511","title":"let-7 Modulates Chromatin Configuration and Target Gene Repression through Regulation of the ARID3B Complex.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26776511","citation_count":42,"is_preprint":false},{"pmid":"22307404","id":"PMC_22307404","title":"miR-125b targets ARID3B in breast cancer cells.","date":"2012","source":"Cell structure and function","url":"https://pubmed.ncbi.nlm.nih.gov/22307404","citation_count":40,"is_preprint":false},{"pmid":"10446990","id":"PMC_10446990","title":"Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10446990","citation_count":39,"is_preprint":false},{"pmid":"16951138","id":"PMC_16951138","title":"ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16951138","citation_count":37,"is_preprint":false},{"pmid":"22751132","id":"PMC_22751132","title":"Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22751132","citation_count":31,"is_preprint":false},{"pmid":"21307092","id":"PMC_21307092","title":"Apical ectodermal ridge morphogenesis in limb development is controlled by Arid3b-mediated regulation of cell movements.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21307092","citation_count":31,"is_preprint":false},{"pmid":"26121572","id":"PMC_26121572","title":"ARID3B Directly Regulates Ovarian Cancer Promoting Genes.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26121572","citation_count":29,"is_preprint":false},{"pmid":"32061921","id":"PMC_32061921","title":"ARID3A and ARID3B induce stem promoting pathways in ovarian cancer cells.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32061921","citation_count":26,"is_preprint":false},{"pmid":"25327563","id":"PMC_25327563","title":"ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25327563","citation_count":22,"is_preprint":false},{"pmid":"24704276","id":"PMC_24704276","title":"Differential expression of ARID3B in normal adult tissue and carcinomas.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24704276","citation_count":19,"is_preprint":false},{"pmid":"31415216","id":"PMC_31415216","title":"LIN28-let-7 axis regulates genes in immortalized human trophoblast cells by targeting the ARID3B-complex.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31415216","citation_count":16,"is_preprint":false},{"pmid":"22860069","id":"PMC_22860069","title":"ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22860069","citation_count":16,"is_preprint":false},{"pmid":"28849241","id":"PMC_28849241","title":"A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28849241","citation_count":14,"is_preprint":false},{"pmid":"25336743","id":"PMC_25336743","title":"Arid3b is essential for second heart field cell deployment and heart patterning.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25336743","citation_count":13,"is_preprint":false},{"pmid":"33649863","id":"PMC_33649863","title":"Distinct and overlapping roles of ARID3A and ARID3B in regulating E2F‑dependent transcription via direct binding to E2F target genes.","date":"2021","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33649863","citation_count":12,"is_preprint":false},{"pmid":"25740147","id":"PMC_25740147","title":"BDP-30, a systemic resistance inducer from Boerhaavia diffusa L., suppresses TMV infection, and displays homology with ribosome-inactivating proteins.","date":"2015","source":"Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/25740147","citation_count":11,"is_preprint":false},{"pmid":"14510719","id":"PMC_14510719","title":"Assessment of inhaled BDP-dose dependency of exhaled nitric oxide and local and serum eosinophilic markers in steroids-naive nonatopic asthmatics.","date":"2003","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14510719","citation_count":10,"is_preprint":false},{"pmid":"27537840","id":"PMC_27537840","title":"Arid3b Is Critical for B Lymphocyte Development.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27537840","citation_count":10,"is_preprint":false},{"pmid":"26519881","id":"PMC_26519881","title":"Critical role of ARID3B in the expression of pro-apoptotic p53-target genes and apoptosis.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26519881","citation_count":8,"is_preprint":false},{"pmid":"27512077","id":"PMC_27512077","title":"ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.","date":"2016","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/27512077","citation_count":8,"is_preprint":false},{"pmid":"16315785","id":"PMC_16315785","title":"Effect of beclomethasone dipropionate (BDP) as extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis.","date":"2005","source":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","url":"https://pubmed.ncbi.nlm.nih.gov/16315785","citation_count":6,"is_preprint":false},{"pmid":"25120063","id":"PMC_25120063","title":"ARID3B expression in primary breast cancers and breast cancer-derived cell lines.","date":"2014","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/25120063","citation_count":4,"is_preprint":false},{"pmid":"17615501","id":"PMC_17615501","title":"[A multicenter, open-label, randomized comparison of suppressive effects on asthmatic inflammation of lower airways and improved effects on health-related QOL between HFA-BDP and fluticasone propionate].","date":"2007","source":"Arerugi = [Allergy]","url":"https://pubmed.ncbi.nlm.nih.gov/17615501","citation_count":3,"is_preprint":false},{"pmid":"9203805","id":"PMC_9203805","title":"Inhaled beclomethasone dipropionate (BDP) prevents seasonal changes in atopic asthmatics.","date":"1997","source":"Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace","url":"https://pubmed.ncbi.nlm.nih.gov/9203805","citation_count":3,"is_preprint":false},{"pmid":"8950946","id":"PMC_8950946","title":"[A comparison of the pharmacological actions between DSCG (disodium cromoglycate) and BDP (beclomethasone dipropionate) in the treatment of bronchial asthma].","date":"1996","source":"Nihon rinsho. Japanese journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8950946","citation_count":2,"is_preprint":false},{"pmid":"37977034","id":"PMC_37977034","title":"ARID3A and ARID3B exert direct regulatory control over the long non-coding RNAs (lncRNAs) MALAT1 and NORAD within the context of non-small cell lung cancer (NSCLC).","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/37977034","citation_count":2,"is_preprint":false},{"pmid":"15841673","id":"PMC_15841673","title":"[The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation].","date":"2005","source":"Arerugi = [Allergy]","url":"https://pubmed.ncbi.nlm.nih.gov/15841673","citation_count":2,"is_preprint":false},{"pmid":"41032419","id":"PMC_41032419","title":"Genetic regulation of ARID3B confers cleft lip with/without cleft palate susceptibility through LLPS-mediated transcriptional program.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41032419","citation_count":0,"is_preprint":false},{"pmid":"41972703","id":"PMC_41972703","title":"Serine 89 Phosphorylation Controls Nuclear Localization and Transcriptional Activity of ARID3B.","date":"2026","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41972703","citation_count":0,"is_preprint":false},{"pmid":"41320129","id":"PMC_41320129","title":"mmu_circ_0000684/hsa_circ_0067098 mediates renal tubular epithelial cells apoptosis to ischemia-reperfusion-induced acute kidney injury by targeting the mmu_miR_671-5p/ARID3B axis.","date":"2025","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/41320129","citation_count":0,"is_preprint":false},{"pmid":"41731686","id":"PMC_41731686","title":"LvID-BDP: A Conotoxin-Based Fluorescent Probe for Visualizing α7 nAChR Expression in Intestinal Inflammation.","date":"2026","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41731686","citation_count":0,"is_preprint":false},{"pmid":"10774164","id":"PMC_10774164","title":"[Immunohistochemical analysis of bronchial mucosa in severe asthmatics treated with long-term, high-dose inhaled BDP].","date":"2000","source":"Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society","url":"https://pubmed.ncbi.nlm.nih.gov/10774164","citation_count":0,"is_preprint":false},{"pmid":"12541826","id":"PMC_12541826","title":"[The effects of BDP on the inflammatory cells in nasal secretions of the patients with allergic rhinitis].","date":"2001","source":"Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/12541826","citation_count":0,"is_preprint":false},{"pmid":"11189187","id":"PMC_11189187","title":"[The effects of BDP on eosinophils in nasal secretions of the patient with allergic rhinilis].","date":"1998","source":"Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/11189187","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.10.648303","title":"Loss of <i>cep57</i> function induces G1 arrest and microcephaly","date":"2025-04-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.10.648303","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.12.25320423","title":"Medicare Payment for Calcium Modification Technologies Among Patients Undergoing Percutaneous Coronary Intervention, 2021-2022","date":"2025-01-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.12.25320423","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21229,"output_tokens":4683,"usd":0.066966},"stage2":{"model":"claude-opus-4-6","input_tokens":8161,"output_tokens":4311,"usd":0.22287},"total_usd":0.289836,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"ARID3B (Bdp) binds to the COOH-terminal region of hypophosphorylated retinoblastoma protein (pRb) through its conserved region, and also binds to the matrix attachment region (MAR) of the immunoglobulin heavy-chain locus, implicating it in transcriptional regulation of differentiation and tissue-specific genes.\",\n      \"method\": \"Co-immunoprecipitation, DNA binding assay (MAR binding)\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding demonstrated by Co-IP and DNA binding assay in single study\",\n      \"pmids\": [\"10446990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ARID3B is required for survival of neural crest during embryogenesis, can immortalize mouse embryonic fibroblasts (MEFs) on its own, and confers malignancy to MEFs when co-expressed with MYCN, demonstrating oncogenic activity and a cooperative role with MYCN in malignant transformation.\",\n      \"method\": \"siRNA knockdown in neuroblastoma cell lines, antisense inhibition, transfection/overexpression, in vivo tumor growth assay in nude mice\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (siRNA, antisense, overexpression, in vivo xenograft) in single rigorous study\",\n      \"pmids\": [\"16951138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Arid3b is expressed in the apical ectodermal ridge (AER) and regulates cell motility and actin cytoskeleton distribution; interference with Arid3b activity causes aberrant AER development due to defective cell movements without changes in cell number or major signaling pathway gene expression.\",\n      \"method\": \"Loss-of-function in mouse and chick embryos (interference constructs), in vitro motility assay, actin cytoskeleton staining (phalloidin), DiI labeling of progenitor cells in vivo\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including in vivo lineage tracing, in vitro motility assay, and cytoskeletal analysis\",\n      \"pmids\": [\"21307092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ARID3B full-length isoform (Fl) is predominantly nuclear but also present at the plasma membrane and cytosol; a novel splice form (Sh) lacking C-terminal exons 5-9 accumulates in cytosol and membrane when overexpressed. ARID3B Fl overexpression induces TNFα-mediated apoptosis by upregulating pro-apoptotic genes (BIM, TNFα, TRAIL, TRADD, TNF-R2, Caspase 10, Caspase 7), while ARID3B Sh does not induce apoptosis.\",\n      \"method\": \"Subcellular fractionation, overexpression of isoforms, gene expression analysis, cell viability assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — localization by fractionation tied to distinct functional outcomes, single lab\",\n      \"pmids\": [\"22860069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ARID3B is a direct target of miR-125b; restoration of miR-125b in MCF7 breast cancer cells decreases ARID3B expression and reduces cell motility and migration. Transient silencing of ARID3B phenocopies miR-125b's effect on cell migration.\",\n      \"method\": \"miRNA overexpression, siRNA knockdown of ARID3B, wound closure and transwell migration assays, phalloidin staining\",\n      \"journal\": \"Cell structure and function\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — miRNA-target relationship validated by KD phenocopy, single lab\",\n      \"pmids\": [\"22307404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In mouse ES cells, Arid3b promotes cell survival (avoiding cell death) while MYCN drives cell cycle progression; epigenetic switching from H3K27me3 to H3K4me3 at the Arid3b and Mycn promoters occurs during somatic reprogramming to iPS cells, and the reverse switch occurs during neural crest differentiation.\",\n      \"method\": \"Gene expression analysis in ES cells, siRNA knockdown, ChIP for histone marks (H3K27me3, H3K4me3), reprogramming assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and functional knockdown, single lab\",\n      \"pmids\": [\"22751132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ARID3B increases ovarian tumor burden in vivo, promotes expression of cancer stem cell markers (CD44, LGR5, CD133/PROM1, Notch2), expands the CD133+ cell population, and enhances paclitaxel resistance.\",\n      \"method\": \"Intraperitoneal xenograft in nude mice, flow cytometry for CD133+, gene expression profiling of ascites cells, drug resistance assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo tumor model with multiple cellular phenotype readouts, single rigorous study\",\n      \"pmids\": [\"25327563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Arid3b is expressed in the myocardium and second heart field progenitors; Arid3b-deficient embryos show cardiac pole shortening, absence of myocardial differentiation, and failed epithelial-to-mesenchymal transition in the atrioventricular canal, with defective second heart field progenitor cell addition to the heart. Downstream targets identified include Bhlhb2 and Lims2.\",\n      \"method\": \"Conditional knockout mouse model, DiI labeling of second heart field progenitors, RNA microarray, histological and immunofluorescence analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo lineage tracing, KO phenotype with defined cellular mechanism, transcriptomic target identification\",\n      \"pmids\": [\"25336743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARID3B directly binds to a defined AT-rich sequence motif at target gene promoters/enhancers (including EGFR enhancer and WNT5A/FZD5 promoter) and induces their expression. ARID3B-driven FZD5 upregulation increases ovarian cancer cell adhesion to extracellular matrix components (collagen IV, fibronectin, vitronectin), with adhesion to collagens II and IV requiring FZD5.\",\n      \"method\": \"ChIP followed by microarray (ChIP-chip), quantitative RT-PCR, motif-finding analysis, overexpression and knockdown, adhesion assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide ChIP combined with functional validation by overexpression and KD, multiple orthogonal methods\",\n      \"pmids\": [\"26121572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARID3B and ARID3A bind to putative ARID3-binding sites in p53 target genes (PUMA, PIG3, p53) in vitro and in vivo; ARID3B silencing blocks transcriptional activation of pro-apoptotic p53 target genes and blocks apoptosis following DNA damage, while ARID3B (but not ARID3A) overexpression induces apoptosis.\",\n      \"method\": \"ChIP (in vivo binding), EMSA (in vitro binding), siRNA knockdown, overexpression, apoptosis assays after DNA damage\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo binding combined with loss-of-function phenotype, single lab\",\n      \"pmids\": [\"26519881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Let-7 miRNA directly represses ARID3B, ARID3A, and importin-9 expression. In the absence of let-7, importin-9 facilitates nuclear import of ARID3A, which forms a complex with ARID3B; the nuclear ARID3B complex recruits histone demethylase KDM4C to reduce H3K9me3 and promotes transcription of stemness factors. ARID3B expression is critical for tumor initiation in let-7-depleted cancer cells.\",\n      \"method\": \"Luciferase reporter assay for miRNA targeting, Co-immunoprecipitation of ARID3A/ARID3B/KDM4C complex, ChIP for H3K9me3, nuclear import assay, tumor initiation assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — complex identified by Co-IP, chromatin modification by ChIP, functional rescue experiments, multiple orthogonal methods\",\n      \"pmids\": [\"26776511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Conditional deletion of Arid3b in mouse bone marrow decreases common lymphoid progenitors and downstream B cell populations while leaving T cell and myeloid lineages intact, and HSC populations are unperturbed, establishing a specific, cell-autonomous role for Arid3b in B cell development.\",\n      \"method\": \"Conditional knockout mouse model, flow cytometry of bone marrow populations\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with defined cellular phenotype, single lab\",\n      \"pmids\": [\"27537840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KSHV lytic switch protein RTA upregulates ARID3B expression; ARID3B relocalizes to viral replication compartments upon lytic reactivation and directly binds A/T-rich elements in the KSHV lytic origin of replication (oriLyt) in a lytic cycle-dependent manner. ARID3B knockdown enhances and overexpression inhibits lytic reactivation.\",\n      \"method\": \"SILAC-based quantitative proteomics, siRNA knockdown, overexpression, DNA affinity assay, ChIP for oriLyt binding, immunofluorescence for relocalization\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including proteomics discovery, ChIP, DNA affinity assay, and bidirectional functional perturbation\",\n      \"pmids\": [\"27512077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In human trophoblast cells, ARID3A, ARID3B, and KDM4C form a triprotein complex (ARID3B-complex) that binds to promoter regions of HMGA1, c-MYC, VEGF-A, and WNT1. ARID3B knockout disrupts this complex and decreases expression of these target genes. LIN28/let-7 axis regulates this complex upstream.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, CRISPR knockout of ARID3B, LIN28 double knockout and double knockin cell lines, qRT-PCR\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — complex formation validated by Co-IP, promoter binding by ChIP, KO rescue approach with multiple orthogonal methods\",\n      \"pmids\": [\"31415216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID3A and ARID3B regulate nearly identical gene sets in ovarian cancer cells, including stemness/cancer genes (Twist, MYCN, MMP2, GLI2, TIMP3, WNT5B); each induces expression of the other, providing evidence of cooperativity. High-level ARID3B (but not ARID3A) induces cell death.\",\n      \"method\": \"Lentiviral transduction with ARID3A-GFP and ARID3B-RFP, RNA-sequencing, expression analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide RNA-seq with defined overexpression, single lab\",\n      \"pmids\": [\"32061921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID3B directly binds to ARID3-binding sites in the promoters of E2F target genes (Cdc2, cyclin E1, p107) in living cells; ARID3B knockdown blocks transcription of these genes and attenuates cell cycle progression. ARID3B overexpression activates cyclin E1 transcription cooperatively with E2F1 and induces cell death.\",\n      \"method\": \"ChIP for direct binding, luciferase reporter assays with ARID3-BS mutations, siRNA knockdown, overexpression, cell cycle analysis\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding confirmed by ChIP and mutational reporter assay, KD with defined cell cycle phenotype\",\n      \"pmids\": [\"33649863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARID3B overexpression increases the expression of lncRNAs MALAT1 and NORAD in NSCLC cells, placing ARID3B upstream of these lncRNAs in the pRB-E2F and p53 regulatory pathways.\",\n      \"method\": \"Overexpression of ARID3A and ARID3B, qRT-PCR/expression analysis of lncRNAs\",\n      \"journal\": \"Pathology, research and practice\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — overexpression with expression readout only, single method, single lab\",\n      \"pmids\": [\"37977034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARID3B undergoes liquid-liquid phase separation (LLPS) to form granules both in vivo and in vitro; this ARID3B-mediated LLPS recruits coactivators SMAD2/3 and establishes enhancer activity necessary for initiating gene expression related to nonsyndromic cleft lip/palate (nsCL/P). Disruption of LLPS rescues migration, apoptosis, and phenotype deficits in zebrafish models.\",\n      \"method\": \"LLPS assays in vitro and in vivo, Co-IP for SMAD2/3 interaction, ChIP for enhancer activity, zebrafish loss-of-function model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — LLPS and coactivator recruitment demonstrated with in vivo functional rescue, single study\",\n      \"pmids\": [\"41032419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Phosphorylation of ARID3B at Serine 89 controls its subcellular localization: phosphorylated ARID3B is confined to the nucleus, while unphosphorylated ARID3B can localize to the nucleus, cytoplasm, and membrane. Phospho-mimetic S89D mirrors wild-type ARID3B in transcriptional regulation and chromatin binding, while phospho-dead S89A shows divergent regulation consistent with altered localization.\",\n      \"method\": \"Site-directed mutagenesis (S89A, S89D phospho-dead/mimetic constructs), phospho-specific antibody generation, subcellular fractionation, ChIP, functional transcriptional assays in ovarian cancer and glioblastoma cells\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with phospho-specific antibody, fractionation, and ChIP functional validation in multiple cell lines\",\n      \"pmids\": [\"41972703\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARID3B is a nuclear DNA-binding transcription factor that binds AT-rich sequence motifs at promoters and enhancers to activate target gene expression (including stemness factors, E2F targets, and pro-apoptotic p53 targets); it forms a triprotein complex with ARID3A and the histone demethylase KDM4C to reduce H3K9me3 and promote chromatin accessibility, is regulated upstream by the LIN28/let-7 miRNA axis and by phosphorylation at Serine 89 (which controls its nuclear confinement), undergoes liquid-liquid phase separation to recruit coactivators such as SMAD2/3, and interacts with hypophosphorylated pRb; loss of ARID3B impairs B cell development, cardiac second heart field deployment, and apical ectodermal ridge maturation, while its overexpression expands cancer stem cell populations and promotes malignant transformation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ARID3B is a nuclear AT-rich interaction domain (ARID) transcription factor that binds AT-rich sequence motifs at promoters and enhancers to activate diverse gene programs—including E2F cell cycle targets, p53 pro-apoptotic targets, stemness factors, and developmental regulators—thereby controlling cell survival, proliferation, and differentiation [PMID:26121572, PMID:33649863, PMID:26519881]. ARID3B forms a triprotein complex with ARID3A and the histone demethylase KDM4C, reducing H3K9me3 to promote chromatin accessibility at target loci; this complex is regulated upstream by the LIN28/let-7 miRNA axis, and ARID3B nuclear confinement is governed by phosphorylation at Serine 89 [PMID:26776511, PMID:31415216, PMID:41972703]. ARID3B undergoes liquid–liquid phase separation to recruit coactivators such as SMAD2/3 and establish enhancer activity, linking its biophysical properties to transcriptional activation during craniofacial development and nonsyndromic cleft lip/palate [PMID:41032419]. Loss of ARID3B impairs B cell development, cardiac second heart field deployment, and apical ectodermal ridge morphogenesis, while its overexpression expands cancer stem cell populations, cooperates with MYCN in malignant transformation, and promotes chemoresistance [PMID:27537840, PMID:25336743, PMID:21307092, PMID:16951138, PMID:25327563].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing ARID3B as a DNA-binding factor with links to cell differentiation: before this work, ARID3B had no known molecular function; Co-IP and DNA binding assays showed it binds hypophosphorylated pRb and the MAR element of the immunoglobulin heavy-chain locus, placing it at the intersection of chromatin architecture and differentiation gene regulation.\",\n      \"evidence\": \"Co-immunoprecipitation with pRb and MAR DNA binding assay in vitro\",\n      \"pmids\": [\"10446990\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No reciprocal validation of the pRb interaction by independent groups\", \"Functional consequence of pRb binding on transcription not tested\", \"MAR binding specificity relative to other ARID family members unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating oncogenic potential: it was unknown whether ARID3B had transforming activity; overexpression immortalized MEFs and cooperated with MYCN to induce tumors in vivo, establishing ARID3B as an oncogene with cooperative activity in malignant transformation.\",\n      \"evidence\": \"siRNA/antisense knockdown in neuroblastoma cells, MEF overexpression, and nude mouse xenograft\",\n      \"pmids\": [\"16951138\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of immortalization (bypass of senescence versus anti-apoptosis) not resolved\", \"Identity of transcriptional targets mediating cooperation with MYCN unknown at this stage\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defining a developmental morphogenetic role: ARID3B's function in embryonic limb development was unexplored; loss-of-function in mouse and chick showed ARID3B is required for AER cell motility and actin cytoskeleton organization, without affecting proliferation or major signaling pathways.\",\n      \"evidence\": \"Loss-of-function constructs in mouse/chick embryos, DiI lineage tracing, phalloidin staining, motility assays\",\n      \"pmids\": [\"21307092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets controlling motility in AER not identified\", \"Whether ARID3B acts through the same ARID3A/KDM4C complex in this context unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linking isoforms and subcellular localization to distinct functional outputs: the full-length nuclear isoform induces TNFα-mediated apoptosis by upregulating pro-apoptotic genes, whereas a short splice form lacking the C-terminal domain does not, establishing that ARID3B's nuclear transcriptional activity is required for its apoptotic function.\",\n      \"evidence\": \"Subcellular fractionation, isoform overexpression, gene expression and viability assays\",\n      \"pmids\": [\"22860069\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only overexpression used; endogenous isoform ratios and regulation not characterized\", \"Direct DNA binding by the short isoform not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connecting ARID3B to epigenetic reprogramming and stemness: ChIP demonstrated bivalent histone switching (H3K27me3 ↔ H3K4me3) at the Arid3b promoter during iPS reprogramming and neural crest differentiation, placing ARID3B within the epigenetic circuitry governing pluripotency and lineage commitment.\",\n      \"evidence\": \"ChIP for H3K27me3/H3K4me3 in mouse ES cells, iPS reprogramming, siRNA knockdown\",\n      \"pmids\": [\"22751132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ARID3B is a cause or consequence of the histone mark switch unresolved\", \"Downstream survival targets in ES cells not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Establishing a cardiac developmental requirement: conditional knockout revealed ARID3B is essential for second heart field progenitor addition and epithelial-to-mesenchymal transition in the atrioventricular canal, identifying Bhlhb2 and Lims2 as downstream targets.\",\n      \"evidence\": \"Conditional knockout mouse, DiI labeling of second heart field progenitors, RNA microarray, histology\",\n      \"pmids\": [\"25336743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding to Bhlhb2/Lims2 promoters not shown\", \"Whether the ARID3A/KDM4C complex is involved in cardiac targets unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating cancer stem cell expansion: ARID3B overexpression expanded CD133+ cells, upregulated stemness markers, and conferred paclitaxel resistance in vivo, linking its transcriptional activity to therapy-resistant cancer stem cell phenotypes.\",\n      \"evidence\": \"Intraperitoneal xenograft, flow cytometry for CD133+, gene expression profiling, drug resistance assay\",\n      \"pmids\": [\"25327563\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect regulation of stemness markers not distinguished\", \"Whether ARID3B acts independently of ARID3A in this context not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining direct genomic targets and a DNA-binding motif: ChIP-chip identified genome-wide ARID3B binding at AT-rich motifs in promoters and enhancers (e.g., EGFR enhancer, WNT5A/FZD5 promoter), and functional assays showed ARID3B-driven FZD5 expression promotes cell–matrix adhesion.\",\n      \"evidence\": \"ChIP-chip, motif analysis, overexpression/knockdown, adhesion assays in ovarian cancer cells\",\n      \"pmids\": [\"26121572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide binding map limited to one cell line\", \"Co-factor requirements for binding specificity not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connecting ARID3B to p53-dependent apoptotic transcription: ARID3B directly binds ARID3 sites in p53 target gene promoters (PUMA, PIG3), and its silencing blocks pro-apoptotic transcription after DNA damage, revealing ARID3B as a required co-activator of p53 apoptotic targets.\",\n      \"evidence\": \"ChIP and EMSA for direct binding, siRNA knockdown, overexpression, apoptosis assays after DNA damage\",\n      \"pmids\": [\"26519881\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physical interaction with p53 protein not demonstrated\", \"Whether ARID3B is needed at all p53 targets or a specific subset unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Elucidating the ARID3B–ARID3A–KDM4C complex and its upstream regulation by let-7: Co-IP identified a triprotein complex whose nuclear assembly depends on importin-9 (itself a let-7 target); the complex reduces H3K9me3 and activates stemness genes, and ARID3B is required for tumor initiation in let-7-depleted cells.\",\n      \"evidence\": \"Co-IP, ChIP for H3K9me3, luciferase miRNA reporter, nuclear import assay, tumor initiation assay\",\n      \"pmids\": [\"26776511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of the triprotein complex not determined\", \"Whether KDM4C recruitment is direct or bridged through ARID3A unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Establishing a specific B-lineage requirement: conditional deletion in bone marrow depleted common lymphoid progenitors and downstream B cells without affecting T or myeloid lineages, defining a cell-autonomous role for ARID3B in B lymphopoiesis.\",\n      \"evidence\": \"Conditional knockout mouse, flow cytometry of bone marrow populations\",\n      \"pmids\": [\"27537840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Target genes mediating B cell specification not identified\", \"Functional redundancy with ARID3A in B lineage not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealing a role in viral DNA replication: ARID3B binds AT-rich elements in the KSHV lytic origin of replication in a lytic cycle-dependent manner and inhibits lytic reactivation, demonstrating that its DNA-binding activity is co-opted during herpesvirus infection.\",\n      \"evidence\": \"SILAC proteomics, ChIP for oriLyt, DNA affinity assay, bidirectional perturbation (siRNA/overexpression), immunofluorescence\",\n      \"pmids\": [\"27512077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which ARID3B inhibits lytic reactivation not resolved\", \"Whether the ARID3A/KDM4C complex participates in viral replication control unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Validating the triprotein complex in a non-cancer developmental context: in trophoblast cells, ARID3B knockout disrupted the ARID3A/ARID3B/KDM4C complex and decreased expression of HMGA1, c-MYC, VEGF-A, and WNT1, confirming the complex as a broadly utilized transcriptional activation module under LIN28/let-7 control.\",\n      \"evidence\": \"Co-IP, ChIP, CRISPR knockout, LIN28 double KO/KI lines, qRT-PCR in trophoblast cells\",\n      \"pmids\": [\"31415216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ARID3B is limiting for complex assembly or acts catalytically not established\", \"Global chromatin accessibility changes upon ARID3B KO not assessed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Establishing ARID3B as a direct co-activator of E2F target genes: ChIP and mutational reporter assays showed ARID3B binds ARID3 sites in E2F target promoters (Cdc2, cyclin E1, p107) and cooperates with E2F1 to activate transcription; its knockdown arrests cell cycle progression.\",\n      \"evidence\": \"ChIP, luciferase reporter with ARID3-BS mutations, siRNA knockdown, overexpression, cell cycle analysis\",\n      \"pmids\": [\"33649863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physical interaction between ARID3B and E2F1 not shown\", \"Whether the ARID3B–E2F cooperation requires KDM4C unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovering liquid–liquid phase separation as a mechanism for enhancer activation: ARID3B forms LLPS granules that recruit SMAD2/3 coactivators to establish enhancer activity required for craniofacial gene expression; disruption of LLPS rescues developmental defects in zebrafish, linking phase separation to nonsyndromic cleft lip/palate.\",\n      \"evidence\": \"In vitro and in vivo LLPS assays, Co-IP for SMAD2/3, ChIP for enhancer marks, zebrafish loss-of-function model\",\n      \"pmids\": [\"41032419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural determinants of ARID3B phase separation not mapped\", \"Whether LLPS is required at all ARID3B-bound enhancers or context-specific unknown\", \"Confirmation in mammalian craniofacial models pending\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identifying Ser89 phosphorylation as a regulatory switch for nuclear confinement: phospho-Ser89 confines ARID3B to the nucleus, while dephosphorylation permits cytoplasmic and membrane localization; phospho-mimetic S89D recapitulates wild-type transcriptional activity and chromatin binding, establishing post-translational control of ARID3B localization and function.\",\n      \"evidence\": \"Site-directed mutagenesis (S89A/S89D), phospho-specific antibody, subcellular fractionation, ChIP, transcriptional assays in multiple cell lines\",\n      \"pmids\": [\"41972703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase(s) phosphorylating Ser89 unknown\", \"Whether phosphorylation affects LLPS or complex formation with ARID3A/KDM4C not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the kinase controlling Ser89 phosphorylation, the structural basis of the ARID3A/ARID3B/KDM4C complex, whether LLPS-mediated enhancer activation is a general or tissue-specific mechanism, and the full extent of functional redundancy versus specialization between ARID3A and ARID3B across developmental and oncogenic contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Ser89 kinase identity unknown\", \"No structural model of the triprotein complex\", \"LLPS contribution to non-craniofacial gene programs untested\", \"Systematic comparison of ARID3A vs ARID3B genome-wide binding and function lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 8, 9, 12, 15]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [8, 9, 10, 13, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 10, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 18]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 9, 10, 13, 15]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 10, 13]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 7, 11]}\n    ],\n    \"complexes\": [\n      \"ARID3A/ARID3B/KDM4C complex\"\n    ],\n    \"partners\": [\n      \"ARID3A\",\n      \"KDM4C\",\n      \"RB1\",\n      \"SMAD2\",\n      \"SMAD3\",\n      \"E2F1\",\n      \"IPO9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}